ORNBV Orion Oyj Class B

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

ORION CORPORATION

PRESS RELEASE

17 JUNE 2025 at 9.00 EEST

        

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

Orion Corporation and Glykos Finland Oy today announced that they have extended their research collaboration and licensing agreement for the development of next-generation antibody-drug conjugates (ADCs).

Under the extended agreement, Orion gains access to Glykos’ proprietary ADC technologies with the potential to expand into three additional programs in the future, in addition to the three ADC programs outlined in the previous agreement. Orion will be responsible for the target selection, research, development, and commercialization of up to three next-generation ADCs, with a focus on solid tumors.

The financial terms of the extended agreement for the three new ADC projects are the same as in the original agreement for the first three projects. Glykos is entitled to milestone payments related to the development of the ADCs and product sales. Glykos is also entitled to receive royalties from the commercial sales generated by the three ADC programs.

“This successful collaboration with Glykos allows us to continue leveraging their advanced ADC technology and underscores our commitment to developing new treatment options for cancer patients,” said Professor Outi Vaarala, Executive Vice President, Innovative Medicines and Research & Development at Orion.

“The extension of our agreement with Orion highlights the potential of our ADC technology. We are excited to expand our collaboration with Orion, whose expertise in cancer therapies and strong clinical development capabilities are crucial for bringing new, effective treatments to cancer patients,” said Juhani Saarinen, CEO of Glykos.

About Orion

Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki

About Glykos

Glykos, focusing on antibody-drug conjugates (ADCs), is dedicated to revolutionizing cancer treatment. Glykos' proprietary hydrophilic payload and linker technology addresses ADC limitations, offering benefits of high efficacy, increased tolerability, excellent pharmacokinetics, and optimized conjugation with any monoclonal antibody. Focused on expanding the therapeutic index, we aim to extend survival and enhance the quality of life for cancer patients. For more information, please visit

Orion Corporation

Contact person:

Antti Haapalinna, Vice President, External Science and Partnering, R&D, Orion Corporation

tel. 0

e-mail:

                                                 

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland



EN
17/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

Orion publishes Half-Year Financial Report for January–June 2025 and h...

Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025 ORION CORPORATION PRESS RELEASE 4 JULY 2025 at 09.00 EEST                    Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025 Orion will publish Half-Year Financial Report for January–June 2025 on Friday, 18 July 2025 at approximately 12.00 noon EEST. The report and related presentation material will be available on the company’s website at after publishing. Webcast and conference call A webcast and a conference call for analysts, in...

 PRESS RELEASE

Orion julkaisee puolivuosikatsauksen 1–6/2025 ja järjestää verkkolähet...

Orion julkaisee puolivuosikatsauksen 1–6/2025 ja järjestää verkkolähetyksen 18.7.2025 ORION OYJ                LEHDISTÖTIEDOTE 4.7.2025 KLO 9.00          Orion julkaisee puolivuosikatsauksen 1–6/2025 ja järjestää verkkolähetyksen 18.7.2025 Orion julkaisee puolivuosikatsauksen 1–6/2025 perjantaina 18.7.2025 noin klo 12.00. Katsaus ja siihen liittyvä esitysmateriaali ovat julkistuksen jälkeen saatavilla yhtiön verkkosivuilla osoitteessa . Verkkolähetys ja puhelinkonferenssi Englanninkielinen verkkolähetys sekä puhelinkonferenssi analyytikoille, sijoittajille ja toimittajille järjestetään ...

 PRESS RELEASE

141,959 Orion Corporation A shares converted into B shares

141,959 Orion Corporation A shares converted into B shares ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 23 June 2025 at 9.30 EEST         141,959 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 141,959 A shares have been converted into 141,959 B shares. The conversion has been entered into the Trade Register on 23 June 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 32,308,783 ...

 PRESS RELEASE

141 959 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi

141 959 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi ORION OYJ        PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT         23.6.2025 KLO 9.30          141 959 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi Orion Oyj:n yhtiöjärjestyksen 3 §:n nojalla on muunnettu 141 959 A-osaketta 141 959 B-osakkeeksi. Muuntaminen on merkitty kaupparekisteriin 23.6.2025. Orion Oyj:n osakkeiden kokonaismäärä on 141 134 278 kpl. Muuntamisen jälkeen A-osakkeita on 32 308 783 kpl ja B-osakkeita 108 825 495 kpl. Yhtiön osakkeiden tuottama äänimäärä muunnon jälkeen on yhteensä...

 PRESS RELEASE

CHMP recommends third indication for darolutamide for patients with ad...

CHMP recommends third indication for darolutamide for patients with advanced prostate cancer ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST           CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the marketing authorisation of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the European Union.Positive opinion is based on results from the pivotal Phase III ARANOTE trial.Pending approval, this broadened in...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch